DLL3-targeted CAR T-cell Therapy in Pre-clinical Models for Small Cell Lung Cancer: Safety, Efficacy, and Challenges

Overview

Journal Transl Lung Cancer Res

Date 2024 Apr 11

PMID 38601455

Authors

Rebecca Y Bellis

Prasad S Adusumilli

Alfredo Amador-Molina

Affiliations

Soon will be listed here.

References

Chen X, Amar N, Zhu Y, Wang C, Xia C, Yang X . Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020; 8(1). PMC: 7304844. DOI: 10.1136/jitc-2020-000785. View

Liu M, Huang W, Guo Y, Zhou Y, Zhi C, Chen J . CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukoc Biol. 2022; 112(4):901-911. DOI: 10.1002/JLB.5MA0122-467R. View

Cherkassky L, Hou Z, Amador-Molina A, Adusumilli P . Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cancer Cell. 2022; 40(6):569-574. PMC: 9197990. DOI: 10.1016/j.ccell.2022.04.006. View

Rudin C, Reck M, Johnson M, Blackhall F, Hann C, Yang J . Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023; 16(1):66. PMC: 10290806. DOI: 10.1186/s13045-023-01464-y. View

Quach H, Skovgard M, Villena-Vargas J, Bellis R, Chintala N, Amador-Molina A . Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy. Cancer Immunol Res. 2023; 11(10):1314-1331. PMC: 10592183. DOI: 10.1158/2326-6066.CIR-22-0840. View

Goebeler M, Bargou R . T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020; 17(7):418-434. DOI: 10.1038/s41571-020-0347-5. View

Zhang Y, Tacheva-Grigorova S, Sutton J, Melton Z, Mak Y, Lay C . Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2023; 29(5):971-985. DOI: 10.1158/1078-0432.CCR-22-2293. View

Zhang H, Yang Y, Li X, Yuan X, Chu Q . Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother. 2023; 159:114248. DOI: 10.1016/j.biopha.2023.114248. View

Restle D, Dux J, Li X, Byun A, Choe J, Li Y . Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma. J Immunother Cancer. 2023; 11(6). PMC: 10314697. DOI: 10.1136/jitc-2022-006609. View

10.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

11.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

12.

Xiong Y, Taleb M, Misawa K, Hou Z, Banerjee S, Amador-Molina A . c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat Cancer. 2023; 4(7):1001-1015. PMC: 10765546. DOI: 10.1038/s43018-023-00573-4. View

13.

Paz-Ares L, Champiat S, Lai W, Izumi H, Govindan R, Boyer M . Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023; 41(16):2893-2903. PMC: 10414718. DOI: 10.1200/JCO.22.02823. View

14.

Giffin M, Cooke K, Lobenhofer E, Estrada J, Zhan J, Deegen P . AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2020; 27(5):1526-1537. DOI: 10.1158/1078-0432.CCR-20-2845. View

15.

Jaspers J, Khan J, Godfrey W, Lopez A, Ciampricotti M, Rudin C . IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023; 133(9). PMC: 10145930. DOI: 10.1172/JCI166028. View

16.

Owen D, Giffin M, Bailis J, Smit M, Carbone D, He K . DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019; 12(1):61. PMC: 6582566. DOI: 10.1186/s13045-019-0745-2. View